Bicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week Low – Here’s Why

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares reached a new 52-week low on Tuesday . The company traded as low as $11.43 and last traded at $11.65, with a volume of 251118 shares. The stock had previously closed at $11.60.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating on the stock. Rodman & Renshaw started coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target on the stock. TD Cowen initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating for the company. Morgan Stanley started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $43.75.

Bicara Therapeutics Trading Down 1.8 %

The company has a fifty day moving average price of $16.65.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). On average, equities research analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Spire Wealth Management acquired a new stake in Bicara Therapeutics during the 4th quarter worth about $31,000. SG Americas Securities LLC acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth approximately $147,000. Cinctive Capital Management LP purchased a new position in Bicara Therapeutics during the third quarter valued at approximately $229,000. Barclays PLC purchased a new position in Bicara Therapeutics during the third quarter valued at approximately $255,000. Finally, Jane Street Group LLC acquired a new position in Bicara Therapeutics in the 3rd quarter valued at approximately $309,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.